JPH07507448A - 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体 - Google Patents
向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体Info
- Publication number
- JPH07507448A JPH07507448A JP6500803A JP50080394A JPH07507448A JP H07507448 A JPH07507448 A JP H07507448A JP 6500803 A JP6500803 A JP 6500803A JP 50080394 A JP50080394 A JP 50080394A JP H07507448 A JPH07507448 A JP H07507448A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- wild
- type human
- acid sequence
- fibrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (37)
- 1.野生型ヒトt−PAアミノ酸配列の103−105番目のいかなる位置にお いてもグリコシル化されており、117番目の位置で機能的な炭水化物構造を欠 いているヒト組織プラスミノーゲン活性化因子(t−PA)変異体であって、野 生型ヒトt−PAと比べて、a)延長した循環半減期および実質的に保持されて いるフィブリン結合性、またはb)向上したin vivoフィブリン溶解力を 示す該変異体。
- 2.野生型ヒトt−PAと比べて循環半減期が延長しかつフィブリン結合性が実 質的に保持されている請求項1に記載の変異体。
- 3.野生型ヒトt−PAの103から105番目のいかなる位置においてもグリ コシル化されているヒトt−PA変異体に比べてフィブリン結合性が向上してお り、かつ117番目の位置で機能的な炭水化物構造を有する請求項2に記載の変 異体。
- 4.野生型ヒトt−PAに比べてin vivoフィブリン溶解力が向上してい る請求項1に記載の変異体。
- 5.野生型ヒトt−PAアミノ酸配列の103番目の位置でグリコシル化されて いる請求項1に記載の変異体。
- 6.野生型ヒトt−PAアミノ酸配列の105番目の位置でグリコシル化されて いる請求項1に記載の変異体。
- 7.103から107番目の位置のグリコシル化がN−結合型である請求項1に 記載の変異体。
- 8.103から105番目の位置のグリコシル化がO−結合型である請求項1に 記載の変異体。
- 9.野生型ヒトt−PAアミノ酸配列の103番目の位置に、Asn−X−Se rまたはAsn−X−Thr(ここに、Xはプロリン以外のどのアミノ酸でもよ い)のトリペプチド配列の一部としてアスパラギンを有する請求項7に記載の変 異体。
- 10.野生型ヒトt−PAアミノ酸配列の103番目の位置にアスパラギン、1 04番目の位置にトリプトファンおよび105番目の位置にセリンを有する請求 項9に記載の変異体。
- 11.野生型ヒトt−PAアミノ酸配列の105番目の位置に、Asn−X−S erまたはAsn−X−Thr(ここに、Xはプロリン以外のどのアミノ酸でも よい)のトリペプチド配列の一部としてアスパラギンを有する請求項7に記載の 変異体。
- 12.野生型ヒトt−PAアミノ酸配列の105番目の位置にアスパラギン、1 06番目の位置にスレオニンおよび107番目の位置にセリンを有する請求項1 1に記載の変異体。
- 13.野生型ヒトt−PAアミノ酸配列の117番目の位置にアスパラギン以外 のアミノ酸を有する請求項1に記載の変異体。
- 14.野生型ヒトt−PAアミノ酸配列の117番目の位置がグルタミンに置換 している請求項13に記載の変異体。
- 15.野生型ヒトt−PAアミノ酸配列の103番目の位置が、Asn−X−S erまたはAsn−X−Thr(ここに、Xはプロリン以外のどのアミノ酸でも よい)のトリペプチド配列の一部としてアスパラギンにさらに置換している請求 項13に記載の変異体。
- 16.野生型ヒトt−PAアミノ酸配列の105番目の位置が、Asn−X−S erまたはAsn−X−Thr(ここに、Xはプロリン以外のどのアミノ酸でも よい)のトリペプチド配列の一部としてアスパラギンにさらに置換している請求 項13に記載の変異体。
- 17.野生型ヒトt−PAアミノ酸配列の107番目の位置がさらにセリンに置 換している請求項16に記載の変異体。
- 18.野生型ヒトt−PAに比べてフィブリン特異性が向上している請求項1に 記載の変異体。
- 19.野生型ヒトt−PAアミノ酸配列の296から302番目または274か ら277番目のアミノ酸領域内で、299番目の位置のアルギニンをアスパラギ ン酸に置換する以外の変更によってフィブリン特異性を向上させる請求項18に 記載変異体。
- 20.該変更が野生型ヒトt−PAアミノ酸配剤の296から300番目の領域 内である請求項19に記載の変異体。
- 21.該変更が野生型ヒトt−PAアミノ酸配列の296、297、298およ び299番目の位置の一カ所またはそれ以上の箇所である請求項20に記載の変 異体。
- 22.該変更が野生型ヒトt−PAアミノ酸配列の296、297、298およ び299番目の位置のリジン、ヒスチジン、アルギニン、アルギニンの各アミノ 酸からアラニンヘの置換である請求項21に記載の変異体。
- 23.野生型ヒトt−PAアミノ酸配列の103番目の位置にAsn−X−Se rまたはAsn−X−Thrのトリペプチド配列の一部としてアスパラギンを有 し、117番目の位置にアスパラギン以外のアミノ酸を有する請求項19に記載 の変異体。
- 24.野生型ヒトt−PAアミノ酸配列の103番目の位置にアスパラギン、1 04番目の位置にトリプトファン、105番目の位置にセリンおよび117番目 の位置にグルタミンを有する請求項23に記載の変異体。
- 25.野生型ヒトt−PAアミノ酸配列の105番目の位置にAsn−X−Se rおよびAsn−X−Thrのトリペプチド配列の一部としてアスパラギンを有 し、117番目の位置にアスパラギン以外のアミノ酸を有する請求項19に記載 の変異体。
- 26.野生型ヒトt−PAアミノ酸配列の105番目の位置にアスパラギン、1 06番目の位置にスレオニン、107番目の位置にセリンおよび117番目の位 置にグルタミンを有する請求項25に記載の変異体。
- 27.次の変異を含むヒトt−PA変異体からなる群より選択される請求項1に 記載の変異体:T103N,N117Z:S105N,A107S,N117Z ;T103N,N117Z,K296A,H297A,R298A,R299A ;S105N,A107S,N117Z,K296A,H297A,R298A ,R299A:T103N,N117Z,R298E,R299E;S105N ,A107S,N117Z,R298E,R299E;T103N,N117Z ,K296Q,H297N,P301S;S105N,A107S,N117Z ,K296Q,H297N,P301S;T103N,N117Z,F274L ,R275H,1276S,K277T;S105,A107S,N117Z, F274L,R275H,276S,K277T。(ここに、Zはアスパラギン (N)以外のどのアミノ酸でもよい)。
- 28.請求項1に記載の変異体をコードするDNA配列。
- 29.請求項28に記載のDNA配列を含み、適当な宿主細胞にてそれを発現で きる複製可能な発現ベクター。
- 30.請求項29に記載のベクターによって形質転換されている宿主細胞。
- 31.請求項30に記載の宿主細胞を培養することを特徴とする、t−PA変異 体をコードするDNAを発現するための方法。
- 32.宿主細胞の培養から変異体を回収する工程をさらに含む請求項31に記載 の方法。
- 33.製薬的に許容し得る担体と混合した治療的有効量の請求項1に記載の変異 体を含有する血管の病気や疾患のための組成物。
- 34.有効量の請求項33に記載の組成物を哺乳類に投与することからなる哺乳 類における血管の肩気や疾患を処置するための方法。
- 35.製薬的に許容し得る担体と混合した治療的有効量の請求項1に記載の変異 体を含有するフィブリン沈着または癒着形成や再形成を予防するための組成物。
- 36.有効量の請求項35に記載の組成物をフィブリンまたは癒着の形成の可能 性のある哺乳類上の部位に投与することからなり、フィブリン沈着または癒着の 形成や再形成を予防するために哺乳類を処置する方法。
- 37.117番目の位置のアミノ酸における機能的な炭水化物構造を除去するこ とを特徴とする、103−105番目のアミノ酸のグリコシル化の結果として減 少した野生型ヒトt−PAのフィブリン結合親和性を実質的に回復させる方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89421392A | 1992-06-03 | 1992-06-03 | |
US894,213 | 1992-06-03 | ||
PCT/US1993/005109 WO1993024635A1 (en) | 1992-06-03 | 1993-05-28 | Tissue plasminogen activator glycosylation variants with improved therapeutic properties |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07507448A true JPH07507448A (ja) | 1995-08-24 |
JP3559559B2 JP3559559B2 (ja) | 2004-09-02 |
Family
ID=25402765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50080394A Expired - Lifetime JP3559559B2 (ja) | 1992-06-03 | 1993-05-28 | 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体 |
Country Status (20)
Country | Link |
---|---|
US (1) | US5612029A (ja) |
EP (2) | EP0643772B1 (ja) |
JP (1) | JP3559559B2 (ja) |
AT (2) | ATE155816T1 (ja) |
AU (1) | AU664469B2 (ja) |
CA (1) | CA2129660C (ja) |
DE (3) | DE69333127T2 (ja) |
DK (2) | DK0643772T3 (ja) |
EE (1) | EE03128B1 (ja) |
ES (2) | ES2203668T3 (ja) |
FI (1) | FI117940B (ja) |
GE (1) | GEP20012448B (ja) |
GR (1) | GR3024806T3 (ja) |
HK (2) | HK1000449A1 (ja) |
IL (1) | IL105883A (ja) |
LU (1) | LU90800I2 (ja) |
NL (1) | NL300050I2 (ja) |
NZ (1) | NZ253556A (ja) |
PT (1) | PT786257E (ja) |
WO (1) | WO1993024635A1 (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7060484B1 (en) | 1993-11-12 | 2006-06-13 | Gilead Sciences, Inc. | Polypeptides and coagulation therapy |
ES2240972T3 (es) * | 1993-11-12 | 2005-10-16 | Gilead Sciences, Inc. | Mutantes de la trombina. |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5510330A (en) † | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
DE4423574A1 (de) * | 1994-07-05 | 1996-01-11 | Boehringer Mannheim Gmbh | Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko |
US5945432A (en) * | 1995-12-22 | 1999-08-31 | The University Of Vermont And State Agricultural College | Thrombolytic agents and thienopyridine derivatives in acute stroke |
AU2660397A (en) * | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
US6083715A (en) * | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
WO1999023115A1 (en) * | 1997-10-31 | 1999-05-14 | Eli Lilly And Company | Glycosylated obesity protein analogs |
US6242473B1 (en) | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
CA2384756C (en) | 1999-11-04 | 2010-09-28 | Genentech, Inc. | Reversed-phase hplc assay for plasminogen activators |
US20030036181A1 (en) * | 2000-06-30 | 2003-02-20 | Okkels Jens Sigurd | Peptide extended glycosylated polypeptides |
US20030149090A1 (en) * | 2001-11-06 | 2003-08-07 | Gehlsen Kurt R. | Compositions for the treatment of infectious diseases |
HUP0600436A3 (en) * | 2001-11-26 | 2010-12-28 | Genentech Inc | Catheter composition and uses thereof |
US7084118B2 (en) * | 2002-02-22 | 2006-08-01 | Genentech, Inc. | Combination treatment with t-PA variant and low molecular weight heparin |
US20060105387A1 (en) * | 2002-08-30 | 2006-05-18 | Prior Christopher P | Transferrin fusion proteins libraries |
US20070014779A1 (en) * | 2002-11-14 | 2007-01-18 | Genentech, Inc. | Plasminogen activator variant formulations |
US7553930B2 (en) | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
US20060104969A1 (en) * | 2004-08-16 | 2006-05-18 | Massachusetts Institute Of Technology | Compositions and methods for enhancing structural and functional nervous system reorganization and recovery |
EP1891214A2 (en) * | 2005-06-02 | 2008-02-27 | Avestha Gengraine Technologies Pvt. Ltd. | A method for optimized production of a recombinant form of tissue plasminogen activator |
US7932084B2 (en) * | 2005-09-08 | 2011-04-26 | University Of Virginia Patent Foundation | Methods and compositions for growing adipose stem cells |
WO2007120818A2 (en) * | 2006-04-12 | 2007-10-25 | Massachusetts Institute Of Technology | Compositions and methods for inhibiting adhesions |
AU2007238608A1 (en) * | 2006-04-14 | 2007-10-25 | Massachusetts Institute Of Technology | Identifying and modulating molecular pathways that mediate nervous system plasticity |
CA2661012C (en) | 2006-08-29 | 2019-03-19 | Genentech, Inc. | Method of treating stroke with thrombolytic agent |
US8835170B2 (en) * | 2006-10-06 | 2014-09-16 | University Of Virginia Patent Foundation | Methods and compositions useful for diabetic wound healing |
US8916148B2 (en) | 2006-11-07 | 2014-12-23 | Genentech, Inc. | Tissue plasminogen activator variant uses |
KR100834561B1 (ko) | 2006-12-08 | 2008-06-02 | 가톨릭대학교 산학협력단 | 크링글 도메인 1 및 2로 이루어진 비-글리코실화 재조합단백질, 그 제조 방법 및 이를 포함하는 조성물 |
EP2289542A1 (en) | 2009-08-31 | 2011-03-02 | PAION Deutschland GmbH | Treatment of neurological or neurodegenerative disorders |
EP2289541A1 (en) | 2009-08-31 | 2011-03-02 | PAION Deutschland GmbH | Treatment of neurological or neurodegenerative disorders |
US20130122076A1 (en) * | 2011-11-11 | 2013-05-16 | Mathew Gelfand | Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease |
US10188706B2 (en) | 2012-07-05 | 2019-01-29 | Hadasit Medical Research Services & Development Limited | Plasminogen activator mutants as anti-fibrinolytic agents |
WO2014089327A1 (en) | 2012-12-05 | 2014-06-12 | National Jewish Health | Treatment for airway cast obstruction |
CN103159860B (zh) * | 2013-04-07 | 2014-09-24 | 旭华(上海)生物研发中心有限公司 | 重组组织型纤溶酶原激活剂及其制备方法与用途 |
US10220008B2 (en) | 2013-08-14 | 2019-03-05 | Stc.Unm | Treatment and prevention of stroke and other neurological disorders |
EP3708226A1 (en) * | 2014-11-03 | 2020-09-16 | Thrombolytic Science, LLC | Methods and compositions for safe and effective thrombolysis |
WO2018141909A1 (en) | 2017-02-03 | 2018-08-09 | Acticor Biotech | Inhibition of platelet aggregation using anti-human gpvi antibodies |
CN110913890A (zh) | 2017-05-16 | 2020-03-24 | 国家医疗保健研究所 | 用于治疗急性缺血性中风的方法和药物组合物 |
US11154596B2 (en) | 2017-06-16 | 2021-10-26 | Thrombolytic Science, Llc | Methods for thrombolysis |
EP3806833A1 (en) | 2018-06-15 | 2021-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity |
WO2021148439A1 (en) | 2020-01-21 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stimulating cerebrovascular function |
WO2021249974A1 (en) | 2020-06-09 | 2021-12-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fucoidan-functionalized polysaccharide particles with t-pa for targeted thrombolytic therapy |
WO2023156683A1 (en) | 2022-02-21 | 2023-08-24 | Acticor Biotech | Treatment of cardiovascular diseases using anti-human gpvi antibodies |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
NL8003402A (nl) | 1980-06-11 | 1982-01-04 | Leuven Res & Dev Vzw | Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking. |
GR79202B (ja) | 1982-05-05 | 1984-10-22 | Genentech Inc | |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
WO1984001960A1 (en) * | 1982-11-11 | 1984-05-24 | Beecham Group Plc | Pharmaceutically active compounds |
DE3382389D1 (de) * | 1982-12-14 | 1991-10-02 | South African Inventions | Plasminogenaktivator. |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4658830A (en) * | 1984-08-08 | 1987-04-21 | Survival Technology, Inc. | Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms |
US4753879A (en) * | 1984-08-27 | 1988-06-28 | Biogen N.V. | Modified tissue plasminogen activators |
NZ213647A (en) * | 1984-10-01 | 1989-05-29 | Integrated Genetics Inc | Recombinant human tissue plasminogen activator (tpa) modified in n-linked glycosylation pattern |
DE3537176C2 (de) * | 1984-10-18 | 1994-06-09 | Zymogenetics Inc | Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
EP0201153A3 (en) * | 1985-02-09 | 1987-10-07 | Beecham Group Plc | Modified enzyme and process for its preparation |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GR860875B (en) * | 1985-04-04 | 1986-07-29 | Beecham Group Plc | Novel compounds |
HU206520B (en) * | 1985-04-22 | 1992-11-30 | Genentech Inc | Process for producing new human tissue plasminogen activator /tpa/ mutants and pharmaceutical compositions containing them |
US4929444A (en) * | 1985-05-28 | 1990-05-29 | Burroughs Wellcome Co. | Low pH pharmaceutical formulation containing t-PA |
HU200695B (en) * | 1985-05-28 | 1990-08-28 | Wellcome Found | Process for producing stable pharmaceutical compositions comprising tissural plasminogene activator |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
ZW14486A1 (en) * | 1985-07-29 | 1986-10-22 | Smithkline Beckman Corp | Pharmaceutical dosage unit |
US4960702A (en) * | 1985-09-06 | 1990-10-02 | Codon | Methods for recovery of tissue plasminogen activator |
ATE83153T1 (de) * | 1985-09-10 | 1992-12-15 | Eisai Co Ltd | Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung. |
GB8528321D0 (en) * | 1985-11-18 | 1985-12-24 | Ciba Geigy Ag | Modified fibrinolytic agents |
EP0289508A1 (en) * | 1985-12-20 | 1988-11-09 | The Upjohn Company | Tissue plasminogen activator (tpa) analogs |
ATE74379T1 (de) | 1985-12-23 | 1992-04-15 | Chiron Corp | Peptidplasminogenaktivatoren. |
DK43387A (da) * | 1986-01-29 | 1987-07-30 | Beecham Group Plc | Fibrinolytisk enzym |
EP0293394B2 (en) * | 1986-01-31 | 2003-10-29 | Genetics Institute, LLC | Novel thrombolytic proteins |
IE81073B1 (en) * | 1986-03-18 | 2000-01-12 | Genentech Inc | Modified human tissue-type plasminogen activator and its preparation |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
AU7090687A (en) | 1986-04-02 | 1987-10-08 | Beecham Group Plc | Modified tissue-type plasminogen activators |
PT84588B (en) | 1986-04-02 | 1989-05-09 | Beecham Group Plc | Process for preparing a fibrinolytic enzyme |
PT84589B (en) * | 1986-04-02 | 1989-05-09 | Beecham Group Plc | Process for preparing a fibrinolytic enzyme |
DE3643158A1 (de) * | 1986-04-21 | 1987-11-19 | Boehringer Mannheim Gmbh | Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung |
JPH0761266B2 (ja) * | 1986-07-03 | 1995-07-05 | 株式会社ミドリ十字 | 変異ヒトプロウロキナ−ゼ |
DK345087A (da) * | 1986-07-11 | 1988-01-12 | Novo Industri As | Modificeret vaevsplasminogenaktivator |
GB8619098D0 (en) * | 1986-08-05 | 1986-09-17 | Wellcome Found | Combination |
EP0266032A1 (en) * | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
WO1988005081A2 (en) * | 1986-12-30 | 1988-07-14 | Cetus Corporation | Novel plasminogen activator |
GB8705377D0 (en) * | 1987-03-07 | 1987-04-08 | Beecham Group Plc | Compounds |
NO882226L (no) * | 1987-05-22 | 1988-11-23 | Zymogenetics Inc | Fibrinolytiske proteiner. |
IE67036B1 (en) * | 1987-06-04 | 1996-05-15 | Zymogenetics Inc | Tissue plasminogen activator analogs having modified growth factor domains |
IE64782B1 (en) * | 1987-06-04 | 1995-09-06 | Eisai Co Ltd | Mutant t-PA with kringle replacement |
SE8702562L (sv) * | 1987-06-18 | 1988-12-19 | Kabigen Ab | Nya fibrinolytiska enzymer |
WO1988010119A1 (en) * | 1987-06-22 | 1988-12-29 | Genetics Institute, Inc. | Novel thrombolytic proteins |
US4935237A (en) | 1988-03-21 | 1990-06-19 | Genentech, Inc. | Processes for the preparation of t-PA mutants |
JPH02504102A (ja) * | 1987-06-30 | 1990-11-29 | ジェネンテク,インコーポレイテッド | 血管障害治療のための改良法 |
WO1989000191A1 (en) * | 1987-07-06 | 1989-01-12 | Genetics Institute, Inc. | Novel thrombolytic proteins |
AU1893988A (en) * | 1987-07-13 | 1989-01-19 | Collaborative Research Inc. | Nonglycosylated plasminogen activator and method of preparation |
NZ225880A (en) | 1987-08-21 | 1991-07-26 | Wellcome Found | A complex of polyethylene glycol and tissue plasminogen activator |
IL88247A0 (en) | 1987-11-06 | 1989-06-30 | Genentech Inc | Novel human tissue-type plasminogen activator variant |
US5225540A (en) | 1988-04-26 | 1993-07-06 | Du Pont Merck Pharmaceutical Company | Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life |
US5270198A (en) * | 1988-05-20 | 1993-12-14 | Genentech, Inc. | DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells |
IL90146A (en) | 1988-05-20 | 1994-10-07 | Genentech Inc | Glycosylation derivatives of tissue plasminogen activator |
US5342616A (en) * | 1988-06-20 | 1994-08-30 | The Wellcome Foundation Limited | Method of administering tissue plasminogen activator |
GB8815135D0 (en) * | 1988-06-24 | 1988-08-03 | British Bio Technology | Proteins & nucleic acids |
DK395288D0 (da) * | 1988-07-15 | 1988-07-15 | Novo Industri As | Proteiner |
US5258180A (en) * | 1988-09-02 | 1993-11-02 | Genetech, Inc. | Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment |
US5262170A (en) * | 1988-09-02 | 1993-11-16 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells |
US5108901A (en) | 1988-09-02 | 1992-04-28 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties |
WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US5218092A (en) * | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
US5041376A (en) * | 1988-12-09 | 1991-08-20 | The Board Of Regents Of The University Of Texas System | Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins |
US4980165A (en) * | 1989-01-27 | 1990-12-25 | Genetics Institute, Inc. | Pharmaceutical formulations of plasminogen activator proteins |
AU637791B2 (en) * | 1989-03-06 | 1993-06-10 | Board Of Regents, The University Of Texas System | Serpin resistant chymotrypsin superfamily proteases, particularly pai-1 resistant +-pa, complementary inhibitor mutants; compositions; genes; expression |
US5304482A (en) * | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
ES2038579T3 (es) | 1989-04-28 | 1997-02-16 | Rhein Biotech Proz & Prod Gmbh | Celulas de levadura del genero schwanniomyces. |
FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
US5087572A (en) | 1989-12-01 | 1992-02-11 | Genentech, Inc. | Dna encoding human plasminogen modified at the cleavage site |
US5366730A (en) * | 1989-12-20 | 1994-11-22 | Boehringer Mannheim Gmbh | Stabilized compositions having human tissue type plasminogen activator enzymatic activity |
DE3942142A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | Stabilisierung von glykosyliertem t-pa |
US5246850A (en) * | 1990-07-31 | 1993-09-21 | Genentech, Inc. | DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells |
CA2086835C (en) * | 1990-07-31 | 2002-04-02 | Bruce A. Keyt | Tissue plasminogen activator variants with decreased clearance |
US5242688A (en) * | 1990-12-24 | 1993-09-07 | Eli Lilly And Company | Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants |
-
1993
- 1993-05-28 DK DK93914240.2T patent/DK0643772T3/da active
- 1993-05-28 AT AT93914240T patent/ATE155816T1/de active
- 1993-05-28 PT PT96117264T patent/PT786257E/pt unknown
- 1993-05-28 WO PCT/US1993/005109 patent/WO1993024635A1/en active IP Right Grant
- 1993-05-28 ES ES96117264T patent/ES2203668T3/es not_active Expired - Lifetime
- 1993-05-28 AT AT96117264T patent/ATE246000T1/de active
- 1993-05-28 ES ES93914240T patent/ES2107041T3/es not_active Expired - Lifetime
- 1993-05-28 EP EP93914240A patent/EP0643772B1/en not_active Expired - Lifetime
- 1993-05-28 JP JP50080394A patent/JP3559559B2/ja not_active Expired - Lifetime
- 1993-05-28 GE GEAP19932383A patent/GEP20012448B/en unknown
- 1993-05-28 DK DK96117264T patent/DK0786257T3/da active
- 1993-05-28 DE DE69333127T patent/DE69333127T2/de not_active Expired - Lifetime
- 1993-05-28 EP EP96117264A patent/EP0786257B1/en not_active Expired - Lifetime
- 1993-05-28 DE DE2001199044 patent/DE10199044I2/de active Active
- 1993-05-28 DE DE69312493T patent/DE69312493T2/de not_active Expired - Lifetime
- 1993-05-28 CA CA002129660A patent/CA2129660C/en not_active Expired - Lifetime
- 1993-05-28 NZ NZ253556A patent/NZ253556A/en not_active IP Right Cessation
- 1993-05-28 AU AU43973/93A patent/AU664469B2/en not_active Ceased
- 1993-06-02 IL IL10588393A patent/IL105883A/xx not_active IP Right Cessation
-
1994
- 1994-08-04 FI FI943632A patent/FI117940B/fi not_active IP Right Cessation
- 1994-11-17 EE EE9400401A patent/EE03128B1/xx unknown
-
1995
- 1995-05-08 US US08/436,697 patent/US5612029A/en not_active Expired - Lifetime
-
1997
- 1997-09-22 GR GR970402440T patent/GR3024806T3/el unknown
- 1997-09-23 HK HK97101814A patent/HK1000449A1/xx not_active IP Right Cessation
-
1998
- 1998-01-07 HK HK98100124A patent/HK1001190A1/xx not_active IP Right Cessation
-
2001
- 2001-07-24 NL NL300050C patent/NL300050I2/nl unknown
- 2001-08-06 LU LU90800C patent/LU90800I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07507448A (ja) | 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体 | |
CN1103815C (zh) | 凝血酶突变体 | |
BG60253B2 (bg) | Човешки тъканен плазминогенен активатор | |
JPH0824579B2 (ja) | ヒトウロキナーゼ | |
JPH07147984A (ja) | ポリクリングルプラスミノーゲン活性化因子をコードする遺伝子およびそれを含有するベクター | |
JPS5942321A (ja) | ヒト組織プラスミノ−ゲン活性化因子 | |
AU624158B2 (en) | Variants of plasminogen activators and processes for their production | |
WO1993003061A1 (en) | Hematopoietic stem cell multiplier | |
JP3126381B2 (ja) | 減少されたクリアランスを有する組織プラスミノーゲンアクチベーター変異体 | |
JP3696617B2 (ja) | フィブリン特異性が改善されたt‐PA置換変異体 | |
JPH03505276A (ja) | 再配列された組織プラスミノーゲン活性化因子及びその産生方法 | |
EP0400054A1 (en) | Modified gene sequences encoding modified tpa and products therefrom | |
JP2532193B2 (ja) | 組織プラスミノ―ゲン活性化因子置換変異体 | |
AU619803B2 (en) | Rearranged tissue plasminogen activators and method for producing same | |
JPH02295483A (ja) | Tpaのプロテアーゼ領域中に位置する修飾残基をコードする新しい遺伝子配列 | |
JPH0242981A (ja) | 新規血栓溶解剤とその製法 | |
HU210541A9 (hu) | Zimogén- vagy fibrin-specifikus tulajdonságú, a 296-299 aminosav-tartományban helyettesített szöveti plazminogén aktivátor, ezt kódoló DNS-molekulák, vektorok és gazdasejtek | |
JPH0249586A (ja) | 新規血栓溶解剤とその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040427 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040524 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090528 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100528 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110528 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110528 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120528 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130528 Year of fee payment: 9 |
|
EXPY | Cancellation because of completion of term |